Hanall Biopharma Co., Ltd. (009420.KS) KSC

Currency In KRW

AD

Valuation

Market Cap2.18T
Enterprise Value2.19T
P/E Ratio-540.01
PEG Ratio0.53
Price/Sales Ratio17.65
Price/Book Ratio17.76
Enterprise/Revenue17.7
Enterprise/EBITDA910.78

Fiscal Year

Fiscal YearDecember 31, 2025
Most Recent QuarterMarch 31, 2026

Profitability

Profit Margin-0.03
Operating Margin-0
AD

Management Effectiveness

Return On Assets-0.02
Return On Equity-0.03

Income Statement

Revenue155.18B
Revenue/Share3,044.83
Gross Profit79.1B
EBITDA1.94B
Net Income-5.56B
Diluted EPS-111.55

Balance Sheet

Total Cash36.16B
Total Cash/Share692.14
Total Debt44.2B
Total Debt/Equity0.27
Current Ratio1.6
Book Value Per Share3,107.85

Price History

52-Week Change108.3
52-Week High73,000
52-Week Low25,550
Moving Average 50 Days53,368
Moving Average 200 Days48,793.5

Statistics

Average Volume540,177
Shares Outstanding50.86M
% Held by InstitutionsN/A

Dividend And Splits

Trailing Annual Dividend Rate0
Trailing Annual Dividend Yield0
Payout Ratio0
Last Split Factor10:1
Last Split DateMay 03, 2006
AD